Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Forest Laboratories announced its plan to continue marketing both the Namenda (memantine HCl) 5mg and 10mg tablets, and Namenda XR (memantine HCl) extended-release capsules into the fall of 2014.
Namenda XR capsules are a higher-dose, once-daily formulation of Namenda immediate-release. Both are indicated for the treatment of moderate to severe dementia of the Alzheimer’s type.
RELATED: Alzheimer’s Disease Drug to be Discontinued
In April 2014, Forest had announced its intention to discontinue Namenda 5mg and 10mg tablets by August 15, 2014. Prescribers were urged to transition patients to Namenda XR as soon as possible. Forest noted that the conversion to the extended-release capsules so far has been trending at approximately 40%.
For more information call (844) 873-2823 or visit NamendaXR.com.
